An observational study in Post COVID-19 Condition, sponsored by ANRS, Emerging Infectious Diseases. Completed at 1 site in Vietnam. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by ANRS, Emerging Infectious Diseases · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in COVID-19 by ANRS, Emerging Infectious Diseases — 3 open to participants now, 5 under way, none of them phase 3. COVID-19 · ANRS, Emerging Infectious Diseases.
Among the 14 studies in COVID-19 by ANRS, Emerging Infectious Diseases, this one is one of 2 that started in 2024, is one of 6 observational ones, and was the 12th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →3 of the 14 studies in COVID-19 by ANRS, Emerging Infectious Diseases are open now, in 3 countries. Recruiting first, the newest first:
ANRS, Emerging Infectious Diseases · Sites in France
Ages 18–60 · Healthy volunteers
ANRS, Emerging Infectious Diseases · Sites in France
Ages 18–84 · Healthy volunteers
ANRS, Emerging Infectious Diseases · Sites in France, Italy, Norway
Ages 16+
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 2
First in 2020; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 807 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 227 across the 8 interventional studies, 1,604 across the 6 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
ANRS, Emerging Infectious Diseases is the lead sponsor of 215 studies on the registry; 38 are open to participants now.
1 of the studies in COVID-19 by ANRS, Emerging Infectious Diseases that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05587894ANRS, Emerging Infectious DiseasesOPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in COVID-19 by ANRS, Emerging Infectious Diseases, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to estimate the prevalence of the post-COVID-19 condition in confirmed mild, moderate, and severe COVID-19 adult patients in Hai Phong, Vietnam.
It is a cross-sectional study implemented in Hai Phong (Vietnam) by the Infectious and Tropical Diseases Department of Viet Tiep 2 hospital and the Department of Public Health of the Hai Phong University of Medicine and Pharmacy (HPMU).
The aim is to enroll moderate and severe COVID-19 patients from the 2 following provincial hospitals, Viet Tiep hospital and Kien An hospital, and mild COVID-19 patients from the community level in Hai Phong to assess the burden of post-COVID-19 condition in each patient group (mild, moderate or severe acute COVID-19).
835 participants are aimed to be interviewed through phone calls: 196 participants with mild disease, 289 participants with moderate disease, and 350 participants with severe disease. In case of suspected post-COVID-19 condition, the participant will be proposed to come to Viet Tiep 2 hospital for a study visit i) to confirm the post-COVID-19 condition, ii) to describe symptoms, iii) to evaluate the functional limitations related to the post-COVID-19 condition, and iv) to assess the determinants of the post-COVID-19 condition in patients with mild, moderate, and severe acute COVID-19.
The patients hospitalised in Viet Tiep 2 hospital or Kien An hospital for moderate or severe acute COVID-19 3 to 12 months before inclusion, or registered in the provincial CDC database for mild COVID-19 that occurred 3-12 months before inclusion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The primary endpoint is the proportion of participants who present a post-COVID-19 condition in adult patients with confirmed mild, moderate, and severe COVID-19 in Hai Phong, Vietnam.
According to the WHO definition
Time frame: Day 0
Type and frequency of symptoms of the post-COVID-19 condition.
Time frame: Day 0
Functional limitations among participants with the post-COVID-19 condition.
Time frame: Day 0
Factors related to occurrence of post-COVID-19 condition in adults after mild, moderate, and severe acute COVID-19.
Time frame: Day 0
Ran from Mar 2024 to primary completion in Feb 2025, 11 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: start Dec 2023 → Mar 2024, primary completion May 2024 → Feb 2025 and completion Dec 2024 → Feb 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ANRS, Emerging Infectious Diseases →